Envisia Therapeutics Inc.
Betting implants can best eyedrops in glaucoma
This article was originally published in Start Up
Envisia Therapeutics Inc. is betting that a proprietary method of engineering micro- and nanoparticles of precise size, shape, and chemistry will enable it to develop drugs for direct delivery to various compartments of the eye. The start-up, formed in November 2013 as a spin-out from Liquidia Technologies Inc., has licensed rights to the parent company's Particle Replication in Non-wetting Templates (PRINT) technology to create new ocular therapies.
You may also be interested in...
Placing assets in new companies is a growing trend for biotech start-ups; freed to evolve differently, spin-outs are structured to increase exit options and maximize investor returns. We profile Envisia Therapeutics, F-star Alpha, Onkaido Therapeutics, Seragon Pharmaceuticals, and True North Therapeutics.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.